OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer
BATON ROUGE, La., Oct. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer …